BioStable Surpasses 500 Patients Treated Worldwide with the HAART Devices
HAART Aortic Annuloplasty Devices Simplify and Standardize Aortic Valve Repair
Austin, TX -- BioStable Science & Engineering, Inc., a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, today announced that over 500 patients worldwide have now been treated using the HAART Aortic Annuloplasty Device.
“Many cardiothoracic surgeons recognize that the young aortic insufficiency patient population cannot be treated with percutaneous aortic valve replacement devices and should be treated surgically with aortic valve repair whenever possible.[1] The HAART Aortic Annuloplasty Devices are enabling surgeons to perform successful aortic valve repair across a broad spectrum of this underserved patient population,” says John Wheeler, President and CEO of BioStable Science & Engineering.
While patients have benefited from advances in mitral valve repair procedures for decades, reproducing the same positive results ─ long-term durability, freedom from re-operation and normal life expectancy ─ using aortic valve repair techniques has been challenging. The HAART family of products received clearance from the U.S. Food & Drug Administration in 2017 and provides an attractive surgical solution for patients suffering from aortic valve regurgitation. To date, over 50 heart centers have adopted the HAART technology including five new hospitals in April alone performing their first HAART implant.
“Aortic valve repair has only been provided to a fraction of aortic insufficiency patients. The HAART technologies offer surgeons the means to standardize and simplify the approach to aortic valve repair for consistent, effective outcomes and the opportunity to avoid valve replacement for many more patients,” said Chief of Cardiovascular and Thoracic Surgery at Franciscan St. Francis Heart Center, Marc W. Gerdisch, MD. “We have used the HAART devices in more than two dozen patients, and they have performed exceptionally.”
“As surgeons experience the versatility of our approach, they are becoming increasingly confident using our devices in lieu of alternative aortic repair or replacement methods. We believe increasing awareness of the potential benefits of early surgical intervention in patients with severe aortic insufficiency[2] combined with the growing positive experience with our HAART Technologies will drive a shift towards wider adoption of aortic valve repair,” said Wheeler. “We are excited about our prospects for accelerating adoption of our technologies.”
Related news
-
U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable alternatives The U.S. Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto (rivaroxaban): the...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) regarding reimbursement in France, and the CGuard EPS is being added to the list of reimbursed...
-
IFEMA MADRID will host the Congress of the European Association for Cranio Maxillo Facial Surgery in the Palacio Municipal
This biennial congress comes to Madrid as the Spanish Professor Julio Acero occupies the Presidency of the Association, and it expects to host more than 2.000 attendees from 70 countries. This edition will mean the return to the face-to-face format after the last appointment of the Congress, celebrated in Munich in 2018, and the virtual edition celebrated last summer after the impossibility of holding it in person in Paris in 2020. IFEMA MADRID continues working for the reactivation of the MICE sector in...
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
Customer comments
No comments were found for BioStable Surpasses 500 Patients Treated Worldwide with the HAART Devices. Be the first to comment!